$Mainz Biomed (MYNZ.US)$ The untapped market size for early ...
The untapped market size for early detection of colorectal cancer in the U.S. is significant. According to various sources, approximately one-third of U.S. residents aged 50-75 have never been screened for colon cancer. This represents a considerable gap in the market, especially given that colorectal cancer is the third most common cancer globally.
Specifically, this gap in screening translates into a market opportunity estimated to be over $4 billion annually. This figure is based on the number of potential screenings that could be conducted if more individuals in the target age group were screened using stool DNA tests, such as ColoAlert® by Mainz Biomed [oai_citation:2,Mainz Biomed Provides Half Year 2024 Corporate Update - Mainz Biomed](https://mainzbiomed.com/mainz-biomed-provides-half-year-2024-corporate-update/) [oai_citation:1,Mainz Biomed Provides Half Year 2024 Corporate Update – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=1330-1000969400en-7U3DL8KACN9SFDTEK9UJQ4DSSJ).
This untapped market presents a substantial opportunity for Mainz Biomed offering non-invasive, early detection solutions, especially as awareness and recommendations for regular screening continue to grow in the U.S.
CRC Early Detection and Market Overview
1. Exact Sciences - Cologuard
Type of Test: Stool-based DNA test (detects DNA alterations such as methylation and mutations in genes like NDRG4, BMP3, and KRAS).
Market Position: Captures a substantial portion of the U.S. CRC screening market (possibly 60-70%).
Market Size (2023): Over $2.3 billion in revenue, largely attributed to Cologuard.
2. Guardant Health - Guardant360 Test
Type of Test: Liquid biopsies.
Market Position: Broader market reach due to application across various cancers, not just CRC.
Market Size (2023): Approx. $449 million, with a significant portion from Guardant360.
3. Mainz Biomed - ColoAlert
Type of Test: Stool-based DNA and mRNA test (combines DNA mutations, methylation markers, mRNA biomarkers; uses FIT and AI/machine learning).
Market Position: Awaiting FDA Breakthrough Device Designation. Significant opportunity in the U.S. CRC screening market.
Market Size (Potential): Approx. $1.25 billion annually (remaining untapped market).
4. Epigenomics AG - Epi proColon
Type of Test: Blood-based test.
Market Position: Faces challenges with adoption compared to competitors.
Market Size (2023): Approx. $1.1 million to $2.2 million.
5. Freenome
Type of Test: Blood-based test.
Market Position: Products in development or early commercialization.
Market Size: Information not available.
6. GRAIL - Galleri Test (Acquired by Illumina)
Type of Test: Multi-cancer early detection (screens for multiple cancers, including CRC, with a single blood test).
Market Position: Conducting large-scale clinical studies (e.g., PATHFINDER study).
Market Size: Information not available.
Disclaimer:
The information provided in this post is for informational purposes only and should not be construed as financial, investment, or medical advice. While efforts have been made to ensure the accuracy of the data, please be aware that the information may not represent the latest updates or developments for each company mentioned. Market conditions, company performance, and other factors can change rapidly.
Investing in stocks involves risk, and it is important to conduct your own research and consult with a qualified financial advisor before making any investment decisions. The author of this post is not responsible for any investment decisions made based on the information provided herein.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
In the midst of chaos, there is also opportunity - The Art of War
14Followers
19Following
65Visitors
Follow